1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

David Redfern

 

b)

Position/status

Chief Strategy Officer

 

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3860

19

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

 

e)

Date of the transaction

2024-04-12

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

GSK plc

 

(Registrant)

 

 

Date: April 16, 2024

 

 

 

 

By:/s/ VICTORIA WHYTE

--------------------------

 

 

 

Victoria Whyte

 

Authorised Signatory for and on

 

behalf of GSK plc